Corcept Therapeutics stock carries a raised 2026 outlook
Published on 09/29/2026 at 13:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Corcept Therapeutics stock carries a raised 2026 revenue outlook after second-quarter product revenue reached USD 256.1 million, up 32 percent from the year-earlier period. The July 29, 2026 results also put the company back in quarterly profitability, while its oncology launch added a second commercial growth driver.
Guidance rises after Q2 growth
According to StockTitan, Corcept reported USD 43.0 million of net income, or USD 0.36 in diluted earnings per share, for Q2 2026, compared with USD 35.1 million and USD 0.29 in Q2 2025. Operating expenses reached USD 214.8 million as the company supported the launch of Lifyorli and expanded its Cushing's syndrome business.
The same July 29, 2026 release raised full-year 2026 revenue guidance to USD 1.1 billion-USD 1.2 billion. That compares with the previous USD 950 million-USD 1.05 billion range, giving investors a concrete measure of how management recalibrated expectations after the quarter.
Lifyorli adds a second engine
Korlym and its authorized generic generated USD 208.6 million in Q2 2026, while Lifyorli contributed USD 47.6 million in its first quarter of commercial sales, according to StockTitan. The mix matters because Corcept is no longer relying on one established product to carry the entire revenue base.
Corcept's investor-relations profile describes a commercial-stage business built around selective cortisol modulators for endocrinologic, oncologic, metabolic and neurologic disorders. Its pipeline includes relacorilant and other proprietary compounds, giving the raised sales forecast a broader operational backdrop than a single-quarter earnings rebound.
Analyst target remains above market
H.C. Wainwright reiterated a Buy rating and maintained a USD 165.00 price target on September 18, 2026, according to GuruFocus. MarketBeat lists a consensus target of USD 138.17 and a Moderate Buy rating, while the elevated targets leave execution on Lifyorli and the guidance range as the key valuation tests.
Market value and trading range
Corcept had a USD 12.5 billion market capitalization on September 29, 2026. The stock's NASDAQ 52-week range was USD 28.66-USD 126.38, giving the Q2 growth figures and the raised outlook a market context.
CORT was last at USD 115.63 on NASDAQ on September 28, 2026 at 4:00 p.m. ET. Corcept's next earnings date is November 4, 2026, according to Investing.com.
Corcept Therapeutics stock facts
- Company: Corcept Therapeutics Incorporated
- Ticker: CORT
- Primary exchange: NASDAQ
- Market capitalization: USD 12.5 billion (as of September 29, 2026)
- 52-week range: USD 28.66-USD 126.38 (as of September 29, 2026)
- Sector / Industry: Healthcare / Pharmaceuticals
- Next earnings date: November 4, 2026
